ScienceAlert5h
FDA-Approved Nasal Spray For Depression Is First Of Its Kind
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
IFLScience14h
FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...